Therapeutic resistance: ALL-important mutations

Comment

Sarah Seton-Rogers. Nat Rev Cancer. 2013 Mar.

. 2013 Mar;13(3):151.

doi: 10.1038/nrc3478.

No abstract available

Comment on

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA, Wang J, Hogan LE, Yang JJ, Dandekar S, Patel JP, Tang Z, Zumbo P, Li S, Zavadil J, Levine RL, Cardozo T, Hunger SP, Raetz EA, Evans WE, Morrison DJ, Mason CE, Carroll WL. Meyer JA, et al. Nat Genet. 2013 Mar;45(3):290-4. doi: 10.1038/ng.2558. Epub 2013 Feb 3. Nat Genet. 2013. PMID: 23377183 Free PMC article.
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T, Rabadan R, Ferrando A. Tzoneva G, et al. Nat Med. 2013 Mar;19(3):368-71. doi: 10.1038/nm.3078. Epub 2013 Feb 3. Nat Med. 2013. PMID: 23377281 Free PMC article.